Components of the PANBioRa biomaterial risk assessment system
ANTIBODY TESTING
Patient-specific interactions between biomaterials and the immune system will be assessed using the ground-breaking Mimotope Variation Analysis technology.
BIOMATERIAL TESTING
Biochemical responses of cells to the presence of biomaterials will be monitored in real time and by integrated biosensors. In addition, PANBioRA includes cytotoxicity and genotoxicity tests with microscopic real-time monitoring capacities
CELL TESTING
Real-time electrochemical sensing will be used to determine the cellular response to a given biomaterial. A set of cytokines released to the extracellular environment will be used as biomarkers to assess the cell response to different biomaterials.
ORGAN ON A CHIP
Respiratory epithelium, gut and liver tissues will be miniaturized into organoids on chip to allow the determination of possible systemic and target organ-specific effects in both healthy and disease conditions.
SIMULATIONS
Potential risks that are difficult to assess experimentally – such as explosion hazards or full-scale biomaterial/microbiota interactions - will be covered by simulations developed within the project.
DATA ANALYSIS
The readouts of the modules will be fed into a model developed within PANBioRA using known biocompatible and hazardous materials to provide a quantitative risk assessment.
RISK RATING
PANBioRA will develop a risk rating system that will display the suitability of the tested biomaterial.
PROJECT NEWS
PANBioRA is present at TERMIS World Congress, 4-7 September 2018 in Kyoto, Japan.
Full Article in the Frontiers research topic: "Adverse Reactions to Biomaterials: State of the Art in Biomaterial Risk Assessment, Immunomodulation and In Vitro Models for Biomaterial Testing":
"In...
After the first 6 month of the project, the PANBioRA consortium has achieved significant steps towards the development of a integrated testing method for biomaterials.
Upcoming Events
in Cancun, Mexico
in Vienna, Austria
Latest Tweets
